Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc    MRK

MERCK & CO., INC

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck: Keytruda Combo Meets Main Endpoint in Metastatic Triple-Negative Breast Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
02/12/2020 | 07:28am EDT

By Colin Kellaher

 

Merck & Co. on Wednesday said a phase 3 study of its cancer drug Keytruda in combination with chemotherapy met one of its dual primary endpoints in a form of triple-negative breast cancer.

The Kenilworth, N.J., drug maker said the combination showed a statistically significant and clinically meaningful improvement in progression-free survival in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1.

Merck said the study will continue without changes to evaluate the other primary endpoint of overall survival.

The company said Keytruda's safety profile in the trial was consistent with previous studies, with no new safety signals identified.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC -4.08% 73.8 Delayed Quote.-18.86%
MERCK KGAA -0.78% 89.18 Delayed Quote.-14.70%
PROCTER & GAMBLE COMPANY -0.61% 109.33 Delayed Quote.-12.47%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC
08:17aPfizer Inc. - Medical Professionals across Merck & Co., Inc., Pfizer Inc., an..
AQ
07:28aMERCK : Keytruda Hits a Main Endpoint in Colorectal Cancer Study
DJ
06:46aMERCK : Announces KEYTRUDA® (pembrolizumab) Significantly Improved Progression-F..
BU
06:31aMERCK : to Hold First-Quarter 2020 Sales and Earnings Conference Call on April 2..
BU
03/31MERCK : Intensity Therapeutics Reports Safety Results from First Cohort of the K..
AQ
03/30PDS BIOTECHNOLOGY : Reports Full Year 2019 Financial Results and Provides Busine..
AQ
03/28MERCK : Investigational Drug Vericiguat Significantly Reduced the Risk of the Co..
BU
03/25MERCK : to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
BU
03/23MERCK : Recommends Rejection of TRC Capital's 'Mini-Tender' Offer
AQ
03/23MERCK : Donates Half a Million Protective Masks to New York City
DJ
More news
Financials (USD)
Sales 2020 49 629 M
EBIT 2020 17 805 M
Net income 2020 13 084 M
Debt 2020 15 700 M
Yield 2020 3,13%
P/E ratio 2020 15,0x
P/E ratio 2021 13,8x
EV / Sales2020 4,25x
EV / Sales2021 4,00x
Capitalization 195 B
Chart MERCK & CO., INC
Duration : Period :
Merck & Co., Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 96,05  $
Last Close Price 76,94  $
Spread / Highest target 39,1%
Spread / Average Target 24,8%
Spread / Lowest Target 11,8%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC-18.86%195 141
JOHNSON & JOHNSON-10.10%345 705
ROCHE HOLDING AG1.53%277 060
NOVARTIS-14.15%187 703
PFIZER, INC.-18.96%181 075
NOVO NORDISK A/S7.31%141 503